<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030225</url>
  </required_header>
  <id_info>
    <org_study_id>CR-202</org_study_id>
    <nct_id>NCT00030225</nct_id>
  </id_info>
  <brief_title>Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure</brief_title>
  <official_title>Phase 2 Evaluation of the Vitagen Extracorporeal Liver Assist Device (ELAD) System in the Management of the Patients With Fulminant Hepatic Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vital Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vital Therapies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treatment with the ELAD Bioartificial Liver
      Assist Device is beneficial to patients in Acute Liver Failure either as a bridge to liver
      transplant or bridge to native liver recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current treatment with modalities in Acute Liver Failure still carry unacceptable morbidity
      and mortality. It is hoped that by intervening with ELAD a patient will have an opportunity
      to be bridged to transplant or to avoid transplantation and to have their native liver
      recover.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects reaching 30-Day survival</measure>
    <time_frame>Study Day 30</time_frame>
    <description>30-day survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day transplant-free survival</measure>
    <time_frame>Study Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Fulminant Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>ELAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ELAD, extracorporeal liver assist system and standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care (Control)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care for patients with fulminant hepatic (liver) failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ELAD</intervention_name>
    <arm_group_label>ELAD</arm_group_label>
    <other_name>Extracorporeal Liver Assist Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care (Control)</intervention_name>
    <arm_group_label>Standard of care (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Clinical diagnosis of Fulminant Hepatic Failure with encephalopathy, and coagulopathy

          -  Weight not less than 40 kilograms

          -  Not listed for organ transplant, but no medical contraindications for transplant

        Exclusion Criteria:

          -  Listed for organ transplant at stud entry

          -  History of jaundice for greater than 28 days at screening

          -  Liver dysfunction due to trauma

          -  Concomitant serious disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick J Maguire, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>VitaGen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Millis M, Maguire P, Cronin D, Conjeevarum H, Johnson R, Conlin C, Brotherton J, O'Laughlin R, Triglia D, Piazza R: Continuous Human Liver Support As A Bridge To Transplantation. Hepatology- Vol.30, No.4 October 1999 p168A.</citation>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2002</study_first_submitted>
  <study_first_submitted_qc>February 11, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2002</study_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fulminant Hepatic Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

